NCT04505462

Dietary Therapy in Dialysis Patients

Completed NA Last updated 16 March 2022

What this trial tests

NA trial testing Therapeutic diet in End Stage Renal Disease on Dialysis in 32 participants. Completed in 1 March 2022.

Timeline

28 October 2020

Primary endpoint
10 December 2020

1 March 2022

Quick facts

Lead sponsor	Far Eastern Memorial Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	32
Start date	28 October 2020
Primary completion	10 December 2020
Estimated completion	1 March 2022
Sites	1 location across Taiwan

Drugs / interventions tested

• Therapeutic diet

Conditions studied

• End Stage Renal Disease on Dialysis — all drugs for End Stage Renal Disease on Dialysis →

Sponsor

Far Eastern Memorial Hospital

Who can join

Adults 21 to 99, any sex, with End Stage Renal Disease on Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with end-stage kidney disease have hyperphosphatemia and accumulated uremic toxin level due to decreased urine excretion ability. Unhealthy diet causes altered mineral metabolism, elevated uremic toxin level, immune dysregulation, and inflammation. The investigators hypothesize that therapeutic diet intervention reverses altered mineral metabolism, elevated uremic toxin level, immune dysregulation, and inflammation. In this study, the investigators crafted 7-day special healthy diet to illustrate the clinical implications of therapeutic diet for dialysis patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets.
   Lim YJ, Sidor NA, Tonial NC, Che A, et al · · 2021 · cited 227× · PMID 33668632 · DOI 10.3390/toxins13020142
2. Short-term effects of therapeutic diet on bone turnover markers in hemodialysis patients: an exploratory analysis of a randomized crossover trial.
   Peng YS, Sun WH, Wu HY, Chiu YL, et al · · 2026 · PMID 41699028 · DOI 10.1038/s41598-026-39820-w